The U.S. Food and Drug Administration approved Merck’s Lipfendra, or enlicitide, on July 16, 2026, to lower LDL cholesterol in adults with hypercholesterolemia. It is the first approved oral PCSK9 inhibitor, bringing a drug class previously dominated by injections into the once-daily pill market.
PCSK9 is a protein that reduces the number of LDL receptors available on the liver to remove cholesterol from the blood. Blocking it allows the body to clear more LDL, or “bad” cholesterol. The market has until now been led by injectable therapies such as Amgen’s Repatha and Sanofi and Regeneron’s Praluent.
FDA’s decision was supported by two randomized, double-blind, placebo-controlled trials involving 3,207 adults. Among patients with established atherosclerotic cardiovascular disease or a high risk of developing it, Lipfendra reduced LDL cholesterol by an average of 56% compared with placebo at 24 weeks. In adults with heterozygous familial hypercholesterolemia, the reduction was 59%.
A reduction approaching 60% gives the pill an efficacy profile that can compete with injectable PCSK9 therapies, while its oral format may make the class acceptable to a much broader patient population.
Merck has set a list price of $10.50 per day, or approximately $315 per month, and expects the medicine to become available within weeks. An RBC Capital Markets analyst projected that Lipfendra could generate peak annual sales of about $5 billion by 2034.
The opportunity is not limited to switching patients who already use injectable PCSK9 drugs. A larger market may exist among high-risk patients who remain above recommended LDL targets despite taking statins or other cholesterol medicines.
Injection aversion, insurance authorization requirements and limited access to specialists have all restricted use of existing PCSK9 therapies. Merck argues that a daily pill can be prescribed more readily as an add-on to established oral treatment.
The commercial breakthrough may come not from replacing every injection, but from moving PCSK9 therapy beyond specialist clinics and into routine primary care.
Lipfendra still has an important evidence gap. The approval is based on its ability to lower LDL cholesterol; it has not yet demonstrated that it reduces heart attacks, strokes or cardiovascular deaths. Merck is conducting an outcomes trial to evaluate its effect on cardiovascular morbidity and mortality.
That distinction will matter to insurers. Even with a lower price than some injectable alternatives, payers may require patients to try cheaper statins and other oral therapies before covering Lipfendra.
The $5 billion forecast therefore depends on more than clinical uptake. It will be shaped by reimbursement, prescribing guidelines and the eventual cardiovascular-outcomes data.
The safety results were generally comparable with placebo. In one of the two trials, diarrhea and dizziness occurred more frequently with Lipfendra, while discontinuation rates due to adverse reactions were similar between the treatment and placebo groups.
The approval has changed competition in the PCSK9 market from a contest among injections into a broader fight over convenience, access and the point at which doctors intensify cholesterol treatment.
